(ATRC) AtriCure - Overview
Stock: Ablation, Clip, Probe, Cannula, Instruments
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 49.4% |
| Relative Tail Risk | -4.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -22.74 |
| Character TTM | |
|---|---|
| Beta | 0.941 |
| Beta Downside | 0.985 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.60% |
| CAGR/Max DD | -0.07 |
Description: ATRC AtriCure January 14, 2026
AtriCure, Inc. (NASDAQ:ATRC) designs, manufactures, and sells a portfolio of single-use and reusable devices that enable surgical ablation of cardiac tissue, left-atrial appendage exclusion, and peripheral-nerve cryo-ablation for pain relief. Its product suite includes the Isolator Synergy RF clamps, cryoICE cryo-ablation system, EPi-Sense catheters for persistent atrial fibrillation, the AtriClip left-atrial appendage occluder, and ancillary tools such as Lumitip dissectors and Glidepath guides. Sales are conducted through a mix of independent distributors and a direct sales force across the United States, Asia-Pacific, and other international markets.
In FY 2023 the company reported revenue of approximately $226 million, a year-over-year increase of roughly 20%, while narrowing its net loss to $12 million and ending the year with about $140 million of cash and short-term investments. The atrial-fibrillation (AF) ablation market is estimated at $6 billion globally and is projected to expand at an 8% compound annual growth rate, driven by an aging population and rising prevalence of AF.
Key economic drivers for AtriCure include Medicare and private-insurer reimbursement trends for catheter-based ablation procedures, hospital capital-budget pressures that favor disposable, single-use devices, and the competitive dynamics with larger electrophysiology players such as Medtronic and Boston Scientific. AtriCure’s focus on minimally invasive, single-use technologies positions it to capture share in a market where procedural efficiency and infection-control are increasingly valued.
For a deeper, data-driven valuation framework, you might explore the AtriCure profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -28.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.85 > 1.0 |
| NWC/Revenue: 43.08% < 20% (prev 43.54%; Δ -0.46% < -1%) |
| CFO/TA 0.07 > 3% & CFO 43.1m > Net Income -28.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago 1.22% < -2% |
| Gross Margin: 74.87% > 18% (prev 0.74%; Δ 7413 % > 0.5%) |
| Asset Turnover: 82.89% > 50% (prev 72.77%; Δ 10.13% > 0%) |
| Interest Coverage Ratio: -2.83 > 6 (EBITDA TTM -6.26m / Interest Expense TTM 7.26m) |
Altman Z'' -2.78
| A: 0.35 (Total Current Assets 301.1m - Total Current Liabilities 77.8m) / Total Assets 635.4m |
| B: -0.65 (Retained Earnings -415.0m / Total Assets 635.4m) |
| C: -0.03 (EBIT TTM -20.6m / Avg Total Assets 625.3m) |
| D: -2.61 (Book Value of Equity -414.3m / Total Liabilities 158.9m) |
| Altman-Z'' Score: -2.78 = D |
Beneish M -3.08
| DSRI: 0.99 (Receivables 63.0m/54.9m, Revenue 518.3m/447.6m) |
| GMI: 0.99 (GM 74.87% / 74.29%) |
| AQI: 0.94 (AQ_t 0.45 / AQ_t-1 0.48) |
| SGI: 1.16 (Revenue 518.3m / 447.6m) |
| TATA: -0.11 (NI -28.8m - CFO 43.1m) / TA 635.4m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of ATRC shares?
Over the past week, the price has changed by -2.57%, over one month by -9.18%, over three months by +12.37% and over the past year by -9.47%.
Is ATRC a buy, sell or hold?
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATRC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.8 | 43.4% |
| Analysts Target Price | 52.8 | 43.4% |
| ValueRay Target Price | 38.1 | 3.4% |
ATRC Fundamental Data Overview February 03, 2026
P/B = 3.8552
P/EG = -1.18
Revenue TTM = 518.3m USD
EBIT TTM = -20.6m USD
EBITDA TTM = -6.26m USD
Long Term Debt = 61.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.00m USD (from shortTermDebt, last quarter)
Debt = 76.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.76b USD (1.84b + Debt 76.7m - CCE 147.9m)
Interest Coverage Ratio = -2.83 (Ebit TTM -20.6m / Interest Expense TTM 7.26m)
EV/FCF = 110.3x (Enterprise Value 1.76b / FCF TTM 16.0m)
FCF Yield = 0.91% (FCF TTM 16.0m / Enterprise Value 1.76b)
FCF Margin = 3.09% (FCF TTM 16.0m / Revenue TTM 518.3m)
Net Margin = -5.55% (Net Income TTM -28.8m / Revenue TTM 518.3m)
Gross Margin = 74.87% ((Revenue TTM 518.3m - Cost of Revenue TTM 130.2m) / Revenue TTM)
Gross Margin QoQ = 75.47% (prev 74.54%)
Tobins Q-Ratio = 2.78 (Enterprise Value 1.76b / Total Assets 635.4m)
Interest Expense / Debt = 3.79% (Interest Expense 2.91m / Debt 76.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.2m (EBIT -20.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.87 (Total Current Assets 301.1m / Total Current Liabilities 77.8m)
Debt / Equity = 0.16 (Debt 76.7m / totalStockholderEquity, last quarter 476.5m)
Debt / EBITDA = 11.37 (negative EBITDA) (Net Debt -71.1m / EBITDA -6.26m)
Debt / FCF = -4.45 (Net Debt -71.1m / FCF TTM 16.0m)
Total Stockholder Equity = 464.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.60% (Net Income -28.8m / Total Assets 635.4m)
RoE = -6.20% (Net Income TTM -28.8m / Total Stockholder Equity 464.1m)
RoCE = -3.91% (EBIT -20.6m / Capital Employed (Equity 464.1m + L.T.Debt 61.9m))
RoIC = -3.08% (negative operating profit) (NOPAT -16.2m / Invested Capital 526.7m)
WACC = 9.12% (E(1.84b)/V(1.91b) * Re(9.38%) + D(76.7m)/V(1.91b) * Rd(3.79%) * (1-Tc(0.21)))
Discount Rate = 9.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.32%
[DCF Debug] Terminal Value 65.30% ; FCFF base≈16.0m ; Y1≈10.5m ; Y5≈4.79m
Fair Price DCF = 3.01 (EV 78.4m - Net Debt -71.1m = Equity 149.6m / Shares 49.7m; r=9.12% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 78.80 | EPS CAGR: 123.5% | SUE: 1.58 | # QB: 5
Revenue Correlation: 98.82 | Revenue CAGR: 17.55% | SUE: 1.64 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=-0.000 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.13 | Chg30d=+0.007 | Revisions Net=+1 | Growth EPS=+45.3% | Growth Revenue=+12.3%